Treatment of Calcium Nephrolithiasis Sodium Thiosulfate

Information

  • Research Project
  • 7426132
  • ApplicationId
    7426132
  • Core Project Number
    R43DK075194
  • Full Project Number
    6R43DK075194-02
  • Serial Number
    75194
  • FOA Number
  • Sub Project Id
  • Project Start Date
    9/1/2006 - 19 years ago
  • Project End Date
    8/31/2008 - 17 years ago
  • Program Officer Name
    MULLINS, CHRISTOPHER V.
  • Budget Start Date
    11/13/2006 - 19 years ago
  • Budget End Date
    8/31/2008 - 17 years ago
  • Fiscal Year
    2006
  • Support Year
    2
  • Suffix
  • Award Notice Date
    5/18/2007 - 18 years ago
Organizations

Treatment of Calcium Nephrolithiasis Sodium Thiosulfate

[unreadable] DESCRIPTION (provided by applicant): The broad objective of this proposed research is to determine the effect of sodium thiosulfate on kidney stone formation. The drug will initially be studied in a rat model of nephrolithiasis and if the drug is shown to reduce risk of new stone formation we will study the drug in patients with nephrolithiasis. The long term goal is to bring a new therapy for kidney stones to market. At the present time there are three pharmacologic therapies for calcium nephrolithiasis that have been proven effective in prospective placebo controlled trials, thiazide diuretics, potassium citrate salts, and allopurinol. Sodium thiosulfate is a generic drug that is considered to be safe for use in humans. A single trial showed sodium thiosulfate to be effective in preventing stone formation in patients with recurrent calcium nephrolithiasis, though no formal control group was included in the study. However, little additional data concerning the use of sodium thiosulfate for nephrolithiasis has been published. Recently, sodium thiosulfate has been reported to be effective in treating pathologic soft tissue calcium phosphate deposition in patients with renal failure, supporting the premise that it possesses significant anti-crystal activity. At this time, sodium thiosulfate remains a promising but incompletely studied potential therapeutic agent; in particular there are no clearly defined mechanisms of action that have been established. If we could show that sodium thiosulfate reduces urine saturation of calcium salts, increases urine inhibition of crystallization and/or reduces stone formation in an animal model it would justify the expense and difficulty of a formal human trial. The aims of this proposal are to determine if sodium thiosulfate can reduce calcium oxalate and calcium phosphate stone formation and/or reduce urine crystallization potential in hypercalciuric kidney stone forming rats. Kidney stones are a very common problem, affecting 13% of men and 7% of women in the United States. Over half of people with kidney stones will have a recurrence of stone formation and many of these patients receive treatment to prevent new stones. New, more effective and better tolerated drugs are needed to reduce the recurrence of kidney stones in these patients. [unreadable] [unreadable] [unreadable]

IC Name
NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES
  • Activity
    R43
  • Administering IC
    DK
  • Application Type
    6
  • Direct Cost Amount
  • Indirect Cost Amount
  • Total Cost
    164683
  • Sub Project Total Cost
  • ARRA Funded
  • CFDA Code
    847
  • Ed Inst. Type
  • Funding ICs
    NIDDK:164683\
  • Funding Mechanism
  • Study Section
    ZRG1
  • Study Section Name
    Special Emphasis Panel
  • Organization Name
    LITHOLINK CORPORATION
  • Organization Department
  • Organization DUNS
  • Organization City
    CHICAGO
  • Organization State
    IL
  • Organization Country
    UNITED STATES
  • Organization Zip Code
    606123502
  • Organization District
    UNITED STATES